International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/

Vol. 51 No. 2 July 2025, pp. 212-230

Artificial Womb And Placenta: A New Era In Maternal Care: Review

Maged Naser [1], Mohamed M. Nasr [2], Lamia H. Shehata [3]

[1] Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn,
[2] Consultant of General and Endoscopic Surgery (MD, FRCS)
[3] Care National Hospital, Department of Radiology
Corresponding Author: Maged Naser

Abstract: In 2017, a team of researchers in Philadelphia introduced what is considered the nearest equivalent to an artificial womb (AW) thus far. The 'biobag', if successful as suggested by initial animal tests, could transform neonatal intensive care. Currently, premature infants born before 22 weeks have no chance of survival. For a considerable time, there have been no noteworthy enhancements in the survival rates or long-term complications for preterm infants at the viability limit. Anticipation surrounds artificial womb technology (AWT), which might positively influence these odds and is eagerly awaited for medical use. It is crucial to determine whether AWT serves as an extension of existing intensive care or represents a completely new paradigm. This inquiry is vital for deciding the appropriate timing and manner in which the biobag should be utilized with human entities. This paper explores the underlying science of AWT and proposes two main arguments. Firstly, AWT is fundamentally different from traditional intensive care. Clarifying why AWT should be viewed as separate is important as it introduces distinct ethical and legal considerations. Secondly, these considerations need to be articulated without relying on loaded language that describes the 'human being growing in the AW'. The term 'human being in an AW' does not accurately capture the nature of the subject, which is neither a fetus nor an infant, as the associations tied to these terms could lead to misunderstanding. Consequently, the term 'gestateling' should be embraced to define this new form of human reproduction: a developing human being presents outside the womb. While this paper does not aim to resolve all ethical challenges related to AWT, it offers important insights that will facilitate the better formulation of ethical inquiries for future investigation.

Keywords: fetal viability, neonatal care, reproductive health, embryos and fetuses

I. Introduction

In early 2017, a breakthrough announcement highlighted the development of the closest approximation to an artificial womb (AW) seen so far. The 'biobag' effectively nurtured lamb fetuses at the current threshold of viability. All the lambs that developed in the biobag emerged in good health, apparently avoiding typical issues associated with preterm delivery (1). The biobag supports partial ectogenesis: the cultivation of a fetus in an AW during a segment of pregnancy after being moved from the mother's womb (2). It holds significant promise for a future where advanced technology could lead to improved long-term outcomes for premature infants.

Singer and Wells proposed that technologies allowing human beings to be artificially gestated would come about 'by chance' as advancements in neonatal intensive care (NIC) (3). Others suggest that partial ectogenesis already partially exists (4); NIC is one of the notable triumphs of modern medicine. Although medical advancements have continuously aided increasingly premature infants(5), we contend that the biobag is not just another enhancement in traditional NIC but represents a completely innovative method. Acknowledging the uniqueness of artificial womb technology (AWT) is essential in conversations about prospective

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

clinical use to avert detrimental choices affecting those involved (6). Because their usage of AWT will have the same clinical purpose as NIC, physicians may easily ignore this distinction, hence it is necessary to draw attention to it. In order to give crucial background for ethical discussion, we first examine the current restrictions on NIC and the potential for AWT. Second, we contend that AWT will question preconceived notions about viability, a term that describes a developing human being's capacity to endure outside of the womb.(6)We contend that AWT will probably be employed to enable partial ectogenesis after the currently accepted viability barrier of 24 weeks from conception. A fetus that is already developing in utero is moved to an AW to continue gestating ex utero during partial ectogenesis. This procedure differs from total ectogenesis, which is the process of creating an embryo by in vitro fertilization that is fully gestated in an AW.(2)A more remote pros-pect that raises some unique ethical concerns is the use of biobags for full ectogenesis.

As a result, this work does not address it. A terminology issue raised by partial ectog-enesis will be looked at. To avoid the ethical ties that current terminologies suggest, which muddy the conversation, new phrases should be established to characterize the AW's topic. A developing human being going through ex utero gestation is referred to as "gestateling."Lastly, we contend that AWT and traditional rescue systems should be viewed as fundamentally different. We give three explanations for the difference: inherent distinctions between AWT and NIC characteristics, distinctions between each technology's subjects and additional possible applications for AWT outside of neonatal rescue. Even though this study does not try to address every ethical issue related to AWT and its experimental application, the important clarifications it offers should be taken into account when developing pertinent ethical topics for further discussion.

1.Artificial Womb

The primary cause of newborn mortality worldwide is preterm birth, which occurs before 37 weeks of pregnancy (7) However, the rapid development of NIC demonstrated how medicine may overcome some of the biological body's innate weaknesses. Over the past few decades, preterms' chances of surviving in affluent nations have been progressively improving. At 28 weeks or fewer, the survival rate of extremely preterm neonates (7) is no longer completely erratic. Preterm births as early as 21 weeks and 6 days have been recorded in "infant incubators."(8). This early survival is uncommon, though. According to a recent study, preterm babies born at 22/23 weeks had a survival rate of just 0.7%.(9) Before this point, there is no chance of survival. If they survive birth, preterms on the viability threshold frequently experi-ence difficulties that can cause serious impairment or even death. (8) Although the number of preterm babies born at 22/25 weeks who survive long enough to get NIC has increased by 44% in the past 20 years, the pattern of mortality and the percentage of people with serious long term health issues have not altered much in a while.(11)

2.Neonatal intensive care's drawbacks

With longer gestation, the frequency and intensity of preterm delivery problems significantly decrease. It is still rare that newborns born before 26 weeks of pregnancy can survive typical problems.(12) Approximately half of preterm infants who survive at 26 weeks have a serious disability for the rest of their lives. For babies born at 23 wks, this rises to 75%.(10) Underdeveloped lungs and respiratory problems, circulatory problems that result in low blood pressure and oxygen deprivation, and an under developed capacity to swallow or suck are the main challenges that preterm infants face.(12) These issues are nearly unavoidable prior to 26 weeks. They can be controlled by nasogastric feeding, external pumps to help with circulation, oxygen administration, and mechanical breathing(12) Each of these therapies, which are all supported in infant incubators, has drawbacks and hazards. Oxygen delivery and mechanical ventilation may harm the lungs or prevent further lung development by causing blood flow abnormalities, external circulation aids can lead to heart failure.(13) Necrotizing enterocolitis (death and intestinal tissue leakage)(14) and infection are major risks associated with nasogastric feeding(12)Some scientists think the clinical potential of NIC has been reached because of the hazards and constraints of therapies.(15) When a newborn is born without the ability to live independently, there is only so much that doctors can do. Because of this, between 60% and 80% of NIC deaths happen after therapies are stopped.(11)

Ethical questions are also raised by conventional NIC.As is frequently the case, when medication is stopped, The goal of all treatment was to prolong the neonate's physical pain and its parent or parents' mental agony. There will still be hazards and similar obstacles to success with potential alternate modes of intervention to those that are commonly used. In light of this, scientists are looking for a different physiological strategy to maintain immature humans by more closely resembling the uterine environment in

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

order to successfully extend gestation (16) In contrast to baby incubators helping preterms with biological processes they are unable to execute effectively for themselves, this includes a support system more akin to an AW, allowing the neonate to continue developing as if they had never been born.

3.The biobag

Early testing revealed that the newly created AW could adequately replicate the uterus environment to support preterm lamb "fetuses" for four weeks. (1) At the established viability threshold of 24 weeks, these lambs were developmental equal to human preterms. All subjects were "delivered" and survived the incubation phase. The success of the Philadelphia-based club made headlines around the world. (17) The biobag has an umbilical cord access, a "pumpless oxygenator circuit," and a zippered bag to keep the patient contained. By preventing external exposure, the enclosed system reduces the chance of infection. The bag provides all the water and nutrients required for the amniotic fluid to exchange continuously. As an "umbilical cord," cannulae deliver necessary oxygen and nutrients to the patient's bloodstream.

The subject's heart must cooperate with an oxygenator in order for circulation to occur, this ensures adequate oxygen and a safe blood pressure by simulating normal placental circulation. (1) In pregnancy, the biobag accurately replicates natural gestation. Every biobag test subject continued to develop and circulate their lungs normally and without infection. (1) It seems that the three most frequent issues that NIC patients face lung development, circulation, and infection have been avoided. An AW system has also been developed by another Australian research team with similar success in animal trials. (16)

Table 1.

Overview of currently described preclinical AP and AW models.

	Artificial Placenta model	**Artificial Womb model**			
	Specifications				
Group	**Michigan, USA**	**Perth, AUS & Sendai, JAP**	**Philadelphia, USA**	**Barcelona, ES**	**Toronto, CAN**
Model name	**VV preemie ECLS**	**Ex-Vivo uterine Environment (EVE)**	**EXTra-uterine Environment for Neonatal Development (EXTEND)**	**-**	**-**
Year of first publication of the current model, (references using the current model)	**2013 [17], [18], [19], [20], [21], [22], [23], [24], [25], [26]**	**2017 [27], [28], [29], [30], [31], [32], [33]§**	**2017 [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45]**	**2023 [46]**	**2021 [47], [48]**

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

	Artificial Placenta model	Artificial Womb model			
	Specifications				
Species, GA at cannulation (range)	Lambs, 130–135	Lambs, 112–115	Lambs, 105 – 117	Lambs, 110–115	Piglets, 91–106
Circuit configuration	VV	VA	VA	VA	VA
Pump, type	Yes, Roller pump	No, N/A	No, N/A	No, N/A	No (11/12), N/A; Yes (1/12), Roller pump
Cannulation, cannula size, abdominal cannula placement	JV/UV (10–12Fr), intraabdominal	UV/2 *UA (10/2 *8Fr), intraabdominal	UV/2 *UA (12/2 *12Fr), Extra-abdominal	UV/2 *UA (10–14Fr) Extra-abdominal	UV/UA (2.1–3.3 mm), Extra-abdominal
Fluid incubation (volume)	No submersion. Fluid-filled endotracheal tube.	Sterile complete submersion (6 L)	Sterile complete submersion (2–4 L)	Semi-closed, complete submersion (10 L)	Sterile complete submersion (NS)
Prophylactic use of antimicrobials	Piperacillin-tazobactam, metronidazole & fluconazole	Meropenem & fluconazole	No	Ceftazidime & meropenem, ultraviolet light sterilization	Piperacillin-tazobactam

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

	Artificial Placenta model	Artificial Womb model			
	Specifications				
Anticoagulation drug (ACT goal)	**Heparin (200–250 s)**	**Heparin (180–220 s)**	**Heparin (150–180 s)**	**Heparin (200–250 s)**	**Heparin (>300 s)**
Corticosteroids (Yes/No, type)	**Yes, methylprednisolone**	**Yes, hydrocortisone**	**No**	**Yes, hydrocortisone**	**Yes, hydrocortisone**
Other medications	**PGE1, erythropoietin, epinephrine (prn), norepinephrine (prn) & dopamine (prn), Diazepam (prn) & buprenorphine (prn).**	**Lipo-PGE1, Erythropoietin & Milrinone (first 24 h).**	**PGE1, Erythropoietin, insulin, buprenorphine (prn) & propofol (prn)**	**PGE1, pRBC**	**PGE1, papaverine, epinephrine (prn)**
Temperature control	**Heat-exchanger (circuit) & dry heated waterbed (bottom).**	**AF warmer, radiant warmer (top) & heating pad (bottom).**	**AF warmer, air warming (top) & dry heated waterbed (bottom).**	**AF warmer**	**Heat-exchanger (circuit) and radiant warmer (top) & heating pad (bottom).**
Max. reported survival (reference)	**17 days [50]**	**7 days [29]**	**28 days [34]**	**7 days [46]**	**2 days [49]**
Successful transition from AP/AW model to normal ventilation	**Yes [19]**	**No***	**Yes [51]**	**No***	**No***

	Artificial Placenta model	Artificial Womb model			
	Specifications				
(reference)					
Long-term survival after weaning from the AP/AW model (duration).	No*	No*	Yes (6 months)	No*	No*
Reported problems and failures leading to mortality (reference)	Cannula-related [20], [25] Cardiac arrhythmia [25] Pericardial tamponade [25] Cardiac arrest [20]	Equipment failure [28], [30] Thrombo-embolism [29] Cannula-related [30]	Equipment failure [42] Cannula-related [42] Umbilical spasm [42] Circuit clotting [42]	Cannula-related [40] Air or Thrombo-embolism Equipment failure	Cannula-related [47], [48] Air/thrombo-embolism [Failure to maintain temperature [47], [48] Heart failure [48]
Perceived advantages	• ▪ Easy access to the fetus.	• ▪ Upon failure of AW, conventional neonatal care can be provided. • ▪ Close mimicking of native physiology.			• ▪ Similar umbilical cord anatomy to humans • ▪ Size-equivalence to human fetuses

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

	Artificial Placenta model	Artificial Womb model			
	Specifications				
Perceived disadvantages	• Divergence of fetal physiology (no fluid submersion, supraphysiologic PaO2, pump-driven flow, chronic intubation with tracheal occlusion, sacrifice of the right jugular vein). • Lack of evidence of feasibility and efficacy in lambs equivalent to human fetuses at the limit of viability. • Use of corticosteroids despite debated long-term adverse effects on the developing brain [41], [42].	• Need for a planned EXIT procedure for cannulation on AW. • Relative inaccessibility of the fetus complicating care and parental bonding. • Intraabdominal umbilical cannulation is not translatable to human fetuses because of vascular tortuosity. • Use of corticosteroids despite debated long-term adverse effects on the developing brain [50].	• Need for a planned EXIT procedure for cannulation on AW. • Relative inaccessibility of the fetus complicating care and parental bonding.	• Need for a planned EXIT procedure for cannulation on AW. • Relative inaccessibility of the fetus complicating care and parental bonding. • Use of corticosteroids despite debated long-term adverse effects on the developing brain [50].	• Need for a planned EXIT procedure for cannulation on AW. • Relative inaccessibility of the fetus complicating care and parental bonding. • Feasibility only demonstrated in a short-term model. • Does not fully recapitulate in utero blood flow, heart rate, or blood gas composition. • Use of corticosteroids despite debated long-

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

	Artificial Placenta model	Artificial Womb model
Specifications		
		term adverse effects on the developing brain [50].

Abbreviations: VV= Veno-venous, AV = Arterio-venous, SA = surface area, PP= polypropylene, PMP= polymethyl pentene, ACT = activated clotting time, NS = not specified, N/A = not applicable, PVC = polyvinyl chloride, prn = '*pro re nata*' (when necessary), PGE1 = prostaglandin E1, pRBC = packed red blood cells

(§) = the groups most recent published study describes the use of a modified circuit (single oxygenator) and an adapted cannulation technique (UV intraabdominal, 2 *UA extra-abdominal), (*) = this might be due to predefined study end-points.

However, because the researchers are more hesitant about the possible therapeutic use of their technology in humans, the AW they built is not the main topic of this paper.

(16)It is difficult to overestimate the significance of these discoveries and their potential to lower morbidity among preterms. Before clinical application can be expected, the biobag needs to be further improved and validated scientifically and safely.(1)

However, it appears likely that human testing will be conducted in a few years.(13) Parents attempting to help premature children or overcome difficult pregnancies will soon clamor for the use of this animal study if the results are replicated with comparable success. Preterms between 23/25weeks gestation are the authors of the Biobag study's "clinical target population.".(1)According to the researchers, the morbidity rate among human preterms alone justifies the deployment of the technology if animal testing continues to provide positive results.(1)They are already anticipating the biobag's clinical use. the team's brief reference to a rationale for experimental use suggests that they do not perceive any significant distinction between the NIC and the AW they have designed that would influence their choice of application. One could argue that, for the time being, there is no difference because the technology's application will have a similar goal to NIC. However, the notion that there is little difference between AWT and existing NIC needs to be criticized due to the repercussions that will be examined.

4.The biobag's subjects

In this part, we show how the biobag is likely to be employed in ways that go above the present viability criterion, and why this calls for the creation of new terms to define the topic of an AW. The biobag study's authors make it clear that the sole goal of their research is to lower the rates of death and disability among "justviable" preterms. They have determined their future clinical target group in accordance with their goal, which is not to "push back" the viability threshold.(1)It makes sense to limit their reach at this point in the experimental process; however, the authors do not say why. In many nations, viability is the stage at which the fetus is granted certain legal safeguards that restrict access to abortion because it offers a medicalized model for abortion and represents a practical compromise between prochoice campaigners and the antiabortion lobby. The researchers might want to keep their work apart of debates about abortion's wider ethical ramifications. The biobag will eventually have the effect of altering, At least, attitudes regarding the location of the viability threshold if it proves to be as effective for human preterms as it has been for animals. The idea of when technology should be utilized to support preterms has changed significantly, despite the obvious limits of traditional NIC. Rescue attempts on preterms as young as 22 weeks are common, despite the current recognized viability cutoff of 24 weeks and the substantial likelihood of problems prior to 26 weeks.Only resuscitation attempts made prior to 22 weeks are considered experimental. Regardless of the anticipated outcome, there is a lot of social conditioning that encourages intervention to save premature babies.(5)Clinicians' desire to perform rescues stems from their best efforts to help the patient in front of them at the parent or parents' request. There is more pressure to try rescue when the newborn is only little less developed than preterms that are

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

frequently sustained.In order to guarantee that their premature newborn receives therapy that gives it a chance at life, parents are frequently prepared to challenge medical professionals. Obstacles can occasionally turn into well known court battles.(52)Medical professionals and parents will immediately advocate for the use of AWT to help preterms who are not far behind the present threshold once AWs can guarantee the consistent and healthy survival of preterms on the viability threshold. We arrived at the present viability standard based on similar trends with conventional NIC. Subjects will beless likely to experience difficulties if the biobag functions as intended than if they are supported with traditional NIC. When AWs are available, clinicians will find greater value in treating younger preterms because of the improved results. The biobag study was ultimately driven by this desire to try something new to help "nearly surviving" preterms.If AWT is effective for older neonates, it seems unlikely that putting younger infants in AWs would be viewed as controversial, with little resistance to attempts.

A terminology issue is shown by the possible use of AWs, which calls into question our comprehension of viability. In the AW, the human being is undergoing artificially induced gestation. In certain situations, it will not be able to exercise any independent capacity for life and will resemble the previability fetus in gestation more onto logically than what is commonly referred to as a "newborn infant. "Preterm babies are referred to using the same terminology as full-term babies. One could argue that referring to a human being who is gestating outside of a womb as a "preterm" or "newborn" is inaccurate given its behavior and developmental stage. When AWT and NIC are compared, this will be examined in more detail. It is noteworthy that the biobag team calls their subjects fetuses. It is also unclear and deceptive to refer to a human being gestating ex utero in the AW as a fetus in an effort to differentiate it from a neonate receiving NIC.By using the term "unborn," the majority of medical definitions of the fetus suggest that it is inside a human gestator. (53) A replacement name that avoids the connotations of using either "newborn" or "fetus" is required because the terms used to designate preterms and fetuses are improper in this context.As a result, we shall call the human being in the AW the "gestateling." This word accurately describes the AW subject and offers helpful clarification. A gestateling is a human being without an autonomous potential for life who is exercising during an exutero pregnancy, regardless of its ability to do so. Through experimental treatment, gestation may soon become a medical reality, which would complicate the ethicallegal debate in neonatology and obstetrics. Not merely another type of critical care We present three arguments in this section for considering AWT to be different from NIC.Scholarly opinion on this topic is conspicuously lacking. To ascertain how biobag experiments involving human beings can start in an ethical way, this inquiry is required.According to Singer and Wells, AWT would merely be a continuation of traditional NIC.As a result, experimentation would be morally right. By merely expanding current interventions, it would not endanger human life but rather comprise related medical procedures carried out to assist a specific patient.(3) Despite efforts to the contrary, AWT may be the only practical technology that can lower the present viability threshold. According to several scientists, traditional NIC has "reached a wall" that will presumably always make it more difficult to maintain younger preterms.(15)AWs take a more radical stance because of their distinct natural characteristics. When thinking about AWT's potential clinical uses in the future and how we could treat impacted parties. Ignoring conceptual differences increases the likelihood of harmful decision-making by or on behalf of the persons involved.

5.The characteristics of AWT Unless their processes significantly differ, two medical technologies can be considered interchangeable when they perform the same function. For instance, comparative invasiveness distinguishes medical and surgical treatments. Underdeveloped humans are supported by both traditional NIC and AWT. However, Hendricks notes that AWT is unique in that it offers more thorough assistance.(54) The preterm "tolerating artificial ventilation" that is necessary for current care is constrained by a natural lung development threshold. Since the AW more closely resembles normal gestation(54) and does not depend on the lungs for gas exchange, this threshold does not limit it. The AW does not seem to be constrained by any natural limit, at least not in relation to lung development. This threshold does not limit the AW because it is more like normal gestation(54) and does not rely on the lungs for gas exchange.At least when it comes to lung growth, the AW does not appear to be limited by any natural limit. Beyond their effects on a single developmental domain, AWT and NIC differ in more subtle ways. AWT can fully replace a human function since it replicates and replaces a biological process rather than attempting to save a human. Consequently, it serves as a step into the automation sector. Regardless of its capabilities, a gestateling must not exhibit any independent capacity for life since the aim of AWT is to treat it as if it had never been conceived.

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

The conventional infant incubator, on the other hand, is made to support only the newborn's developing or current capacity to sustain life. The newborn is therefore partially responsible for self maintenance. However, no such strain is placed on the gestateling during partial ectogenesis. It is not necessary for an AWT subject to perform any autonomous life-sustaining activities. If the AWT were disabled or malfunctioned, an underdeveloped gestateling would die in a catastrophic placental abruption, just as a fetus would in utero.The premature neonate may live for a short while before their vital functions deteriorate, though, if the infant incubator is shut off. however, live for a little period of time until life functions diminished. AWT is more akin to technologies that support people who have lost their brain stem than it is to artificial support systems used for comatose patients whose neural systems are still functioning and still able to coordinate certain vital body processes. In comparison, the latter is more like NIC. Rieder contends that doctors essentially take over the process of making extremely premature children when they perform resuscitation and therapy on them using the only technology now available.(55)While conventional NIC aims to "artificially continue gestation," he contends that it does not provide rescue for extremely premature newborns. He asserts that there is minimal need to defend this finding.(55) However, we contend that his observations are incorrect when applied to traditional NIC, but they are correct when applied to innovations like as the biobag.Rieder confuses gestation (the creative process) with a human being's ongoing development. "Continuing to develop after being born" is not the same as gestation, whether it occurs in utero or outside of it.Long after the gestational process is finished, humans continue to develop, for instance, as part of their ongoing childhood development.(56)However, gestation is unique in that it is a process of formation, and if it is not properly finished, the human being is incapable of supporting themselves. Conventional NIC's limits show that it can only help with life functions that a preterm child is having trouble performing on their own.

A "creative process" is not what conventional NIC is. Gestation, whether in or ex utero, is distinct from ‘continuing to develop after being born’.Human beings continue to develop long after the prenatal phase is complete, for example as part of development extending into infancy.(56)However, gestation is unique in that it is a process of formation, and if it is not properly finished, the human being is incapable of supporting themselves. Conventional NIC's limits show that it can only help with life functions that a preterm child is having trouble performing on their own.While AWT is a "creative process," conventional NIC is not.The environment is another way that AWT and traditional NIC differ from one another.The preterm is exposed and in an atmosphere where some human interaction (skin/skin contact) is feasible despite the fact that intensive help with life functions is completely invasive.

However, the support in the biobag isnearly completely non-invasive, and the gestateling is encapsulated. The gestateling is surrounded by support mechanisms rather than violently invaded.One imagines that the developing human would experience less pain and stress during the AWT process. Less gestateling is needed, thus there is less to upset.Notably, AWT's methodology is so distinct that results will vary and are unknown outside of a single study.The longterm effects of artificial gestation cannot be known at this time or in the near future. Long after being taken out of the biobag, gestatelings could be the focus of a study. The biobag will continue to be a novel experimental treatment for a while.whereas traditional NIC is operating normally.

Some caution should be exercised due to the uncertain ramifications.Theoretically and practically, partial ectogenesis AKT could support a gestateling that is completely incapable of performing any autonomous life processes outside of the womb.It is remarkable how different the subjects possibly supported by each support mechanism are in terms of gestational age and the resulting talents. According to Hendricks, the subject's standing would thus be a crucial differentiator. Since AWT can support something that "does not look like a newborn," we could be more likely to believe that it is unique.(54)It is outside the purview of this research to determine whether the preterm neonate and the gestateling have different moral standings. However, there is a significant disparity in their capacities based on their differences in look and growth.

6.Beyond just another form of intensive care

This distinction is significant when considering the role that technology must play in supporting them. Assume that AWT has the same inherent restrictions as NIC with regard to the subjects it can support and does not further conflate the viability criteria, the subjects' behaviour still differs from one another. The importance of whether or if the subjects helped ensure their own existence has already been emphasized. Additionally, the premature neonate can engage in social interactions, profit from human connections,

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

and integrate into social networks of others. It can engage in direct, physical interaction with other people. Added individuals can collaborate physically with it. The gestateling is shut off from the alfresco apple and does not touch, aroma or collaborate with annihilation added than its bogus gestator. This abreast will access the acumen of and, on occasion, the activity absorbed to anniversary entity. These perceptions will impact, in assorted allusive ways, on the controlling of those surrounding the gestateling.

7.Potential uses of fractional ectogenesis

Finally, AWT introduces opportunities above added active affliction for preterms. Fractional ectogenesis, already AWs are available, could become an audible advance of activity in obstetrics to administer alarming pregnancies. A dangerous, but wanted, pregnancy is not wholly aberrant and the choices at present assume acutely bleak. When pregnancy threatens a woman's life, she is usually brash to acquire an abortion. The another is that she continues the pregnancy acquisitive she survives continued pregnancy to bear a advantageous child, but demography the accident that neither she, nor her fetus, will survive. In 2016, Heidi Loughlin faced this decision afterwards actuality diagnosed with a cancer during pregnancy. Loughlin banned to acquire there was no another to allotment amid her activity and her fetus. She adopted for a third choice: actual pregnancy until 28 weeks and opting for abortive delivery. Unfortunately, the abortive adolescent did not survive continued afterwards delivery.(57) This decision was fractional ectogenesis in action, but afore AWT was available. An AW, were it accessible, may acquire afflicted the odds. AWT ability animate added women with alarming pregnancies to accomplish Loughlin's choice. Its ability alike be that, in future, women ambition to opt for AWT over continuing pregnancy in situations of beneath concern, for archetype to abstain abhorrent affection like morning sickness. AWT is, therefore, audible from accomplishment technologies because it introduces the achievability of the abstraction of gestatelings that would never acquire existed ex utero otherwise. AWT in these situations performs the action of anxiously comestible gestatelings removed from pregnant women and clumsy to sustain themselves.

However, AWT is again functionally not aloof about 'sustaining a fetus/gestateling' but enabling pregnant women to accept an another to pregnancy after risking the accident of the artefact of reproduction. NIC, because of its risks and limitations, will never be advised a reliable pregnancy another to evolution to accredit this choice. If AWT is called as an another to the 'dangerous pregnancy-abortion' dichotomy, an abstraction action will be allotment of the ameliorative action and is additionally experimental. A safe adjustment of extraction, potentially a 'more circuitous and intricate' C-Section charge be developed (58, 59) accordingly involving balloon and error. We are because experimenting on gestatelings and additionally potentially because experimenting on the women who agitated them.

8.Current Analysis and Innovation on Bogus Placenta and Womb Technology

AP and AW models that accept been developed, accept been acknowledged due to an abstruse change that copies fetal and uteroplacental biology. The AW models actualize an ambiance that surrounds the antecedent or fetus with balmy fluids and provides diet and aerial barter .(60-62) Moreover, the AW models, advance a counterbalanced ambiance of affectionate and placental hormones and advance factors, that can be acclimated to abstraction and carbon accustomed fetus growth. Abnormal conditions, such as fetal hypoxia, can additionally be advised and controlled in AW models .(63-66) AW models are additionally important for their role in highlighting and actuality able to actual defects in a fetus' growth. For example, if there is any placental absence because of a curtailment of diet or oxygen to the fetus, it can bind its growth. To carbon this deficiency, automated blast can be restricted, again any botheration in the archetypal can be corrected, alike if the fetus is adversity from astringent pulmonary, diaphragmatic, or cardiac complete malformation(s). The role of axis cells, gene therapy, and pharmacology can be explored in these models, as these ameliorative agents can calmly be delivered to the fetus after any affectionate or placental barriers .(76)

9.Advantages and Abeyant Applications of Bogus Womb Technology

The capital ambition of AW is to accommodate an animal uterus-like environment, so that the fetus can survive after adversity from the accent of preterm birth. While there is no affirmation yet that supports accepted use of an AW (68,69), the neonatal accelerated affliction assemblage that is generally adapted for preterm breed is not consistently acceptable and has weaknesses that could be apparent by use of an AW to abate bloodshed and anguish ante amid preterm breed .(68,70-72) This blazon of technology could additionally abate the accident of Cesarean sections, an above anaplasty that is associated with several risks, such as boundless

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

bleeding, anguish infection, and claret clots(73-76). Moreover, AW technology acquiesces to accomplish surgical operations on the growing fetus, abbreviation the accident of any complications for the pregnant mother, for whom these procedures are chancy .(74,77-82) Another account of ectogenesis is that it provides a controlled ambiance for the fetus to abound in, beneath controlled altitude of temperature, oxygen, nutrition, etc. (74,78,83) Finally, ectogenesis could be accessible for individuals and families' adverse difficulties with conceiving.(78,83-88)

10.Assessing the Limits and Ethical Considerations of AW

Currently, there are several ethical and bioethical issues apropos AW, which charge be addressed .(89) The models used do not replicate the natural capacity of the placenta to transform pulsatile blood flow from the umbilical artery into laminar blood flow in the umbilical vein .(90) Moreover, there is no bright compassionate of the psychological and emotional affects the use of the bogus uterus will accept on parents and consecutive progeny, accustomed the aberration it introduces to the abstraction of accouchement .(91) Concerns accept additionally been aloft about the activity of accepting abreast accord for these procedures, including the use of AW in analytic trials, due to the achievability of advertisement abstraction capacity to hasty physical and psychological damage. When establishing the ambit for beginning research, it is acute to ascertain specific belief for free the adapted use of these technologies .(92)

The appliance of bogus wombs poses an approaching accident to the angle of parenthood. Medical professionals accede that the accustomed mother-child affiliation is benign to both the mother and the child: a axiological and concrete assurance is congenital amid the two bodies during the nine-month evolution period, a band that is not alone emotional, but additionally physiological, acknowledgment to the breeze of hormones. By design, the use of bogus wombs breaks this relationship, and the abiding furnishings of this acute convenance are difficult to predict. The use of bogus wombs appropriately threatens the actual abstraction of motherhood .(93) Moreover, the use of AW has the abeyant to acknowledge or accent disparities in healthcare accessibility: the amount may affectation an albatross to accessibility, and several authors accept accent this impediment as an accessible contributor to the accretion of amusing asperity .(83,94,95)

11.Development of an Artificial Placenta: Future Challenges

Neurologic	• Avoiding trauma and bleeding
	• Demonstrating normal function and development
Cardiovascular	• Maintaining fetal circulation long-term
Pulmonary	• Avoiding trauma and demonstrating lung development
	• Weaning off AP support to conventional ventilation and air breathing

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 2 July 2025, pp. 212-230

11.Development of an Artificial Placenta: Future Challenges

Nutrition	• Optimizing nutrition with enteral feeds
Gastrointestinal	• Ensuring adequate intestinal perfusion
Renal	• Maintaining renal function and electrolyte balance
Infections	• Maintaining sterility
Disease	• Preventing and treating sepsis
Hematologic	• Eliminating anticoagulation
Circuit	• Optimize and automate AP circuit.
	• Miniaturize pump, oxygenator, and cannulas
	• Enhance biocompatibility
Clinical	• Develop clinical criteria to determine which infants will benefit from AP support
	• Develop phase I clinical trial using pairs-matched study design

12.Prospects for Artificial Placenta and Artificial Womb Technology

Extensive analysis is adapted for the applied accomplishing of AP and AW technology as a healthcare action for humans. In the abreast era of abstruse progress, it is acute for committees to actuate the medical account of an accurate technology and differentiate it from innovative experimental constituents designed for research objectives. Moreover, it is acute to accede the abeyant allowances

and ameliorative backdrop of the new beginning accessories and their advised recipients. AP and AW could become accepted analytic procedures, agnate to in vitro fertilization for infertility or fetal activity abutment systems, but all-encompassing bioethics analysis is bare to ascertain the abounding arrangement of ethical issues. AW technology is advancing to serve as an analytical basement for assorted forms of fetal research.

The ambit of this analysis may accommodate the assay of fetal development, analysis of assorted fetal altitude and diseases, a biogenetic engineering, and added accurate investigations. In adjustment to ensure ethical conduct and aegis the rights and well-being of subjects in AW-based research, it will be all-important to apparatus added guidelines that administer animal accountable research. It is acute to appoint in advancing appraisal and modification of accustomed protocols, in adjustment to abide accepted with the latest developments in AW technology and alteration analysis environments. The access of benefits, adherence to ethical principles, and attention of analysis participants can be accomplished through the accomplishing of absolute guidelines.

II. Conclusion

The achievability of evolution ex utero begins with technology initially acclimated as an another to accepted NIC afore accordingly arduous the activity threshold. The biobag, however, is added than a bald addendum of accepted preterm care. It marks an about-face in physiological access for three reasons.

First, AWT replaces a accustomed action rather than facilitating a newborn rescue. Instead of acceptable an premature neonates with functions it is disturbing to accomplish alone, AWT treats its accountable as if had not been born. Unlike a preterm in accelerated affliction does, the gestateling does not accept to exercise any absolute accommodation for life. AWT additionally places the gestateling in a altered environment, the after-effects of which are still unknown. Second, if testing on animal 'just-viable' preterms is successful, the technology is acceptable to be acclimated above the accepted activity threshold. Clinicians and parents accept incentives to try AWT to sustain preterms alone hardly beneath the threshold, alive perceptions of viability. Thus, AWT could sustain preterm with actual altered capacities. These preterms cannot be appropriately declared as either babies or fetuses because they are different in behaviour, area and the action they are undergoing. The appellation 'gestateling' should be acclimated to analyse the developing animal actuality in the AW. Third, AWs accept abeyant analytic uses above accepted accomplishment technologies. AWT ability arise aloof a bigger another to NIC, but its development is added cogent and will accredit the bearing of fractional ectogenesis as a ameliorative action in itself.

Identifying these distinctions is acute to acquaint ethic legal altercation and ensure bigger aegis for afflicted parties. Recognising the aberration in subject, and analogue that ability agreeably be deployed to call it, will additionally anticipate the arrest of amount burdened agreement and accompany accuracy to this discussion. Actuality alert of these differences allows us to accede what, if any, added adjustment is adapted to ensure AWT analysis and its abeyant analytic applications are ethical.

Conflict of Interest

All authors declare no conflicts of interest.

Author Contribution

Authors have equally participated and shared every item of the work.

References

[1]- Partridge, Emily A., et al. "An extra-uterine system to physiologically support the extreme premature lamb." *Nature communications* 8.1 (2017): 15112.

[2]- Gelfand, Scott, and John R. Shook, eds. *Ectogenesis: artificial womb technology and the future of human reproduction*. Vol. 184. Rodopi, 2006.

[3]- Gelfand, Scott, and John R. Shook, eds. *Ectogenesis: artificial womb technology and the future of human reproduction*. Vol. 184. Rodopi, 2006.

[4]- Romanis, Elizabeth Chloe. "Artificial womb technology and the frontiers of human reproduction: conceptual differences and potential implications." *Journal of Medical Ethics* 44.11 (2018): 751-755.

[5]- Simonstein, Frida. "Artificial reproduction technologies (RTs)–all the way to the artificial womb?." *Medicine, Health Care and Philosophy* 9 (2006): 359-365.

[6]- Glover, Jonathan. *Causing death and saving lives: The moral problems of abortion, infanticide, suicide, euthanasia, capital punishment, war and other life-or-death choices*. Penguin UK, 1990.

[7]- Azad, Kishwar, and Jiji Mathews. "Preventing newborn deaths due to prematurity." *Best practice & research Clinical obstetrics & gynaecology* 36 (2016): 131-144.

[8]- Capron, Alexander Morgan, and Vicki Michel. "Law and bioethics." *Loy. LAL Rev.* 27 (1993): 25.

[9]- Pierrat, Véronique, et al. "Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort study." *bmj* 358 (2017).

[10]- Costeloe, Kate L., et al. "Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies)." *Bmj* 345 (2012).

[11]- Lissauer, Tom, and Will Carroll, eds. *Illustrated textbook of paediatrics*. Elsevier Health Sciences, 2017.

[12]- Moore, Tamanna, et al. "Neurological and developmental outcome in extremely preterm children born in England in 1995 and 2006: the EPICure studies." *bmj* 345 (2012).

[13]- Couzin-Frankel, Jennifer. "Fluid-filled 'biobag'allows premature lambs to develop outside the womb." *Science* 25.10.1126 (2017).

[14]- Ormond, Great. "Great Ormond Street Hospital for Children NHS Foundation Trust."

[15]- Hendricks, Jennifer S. "Of Woman Born? Technology, Relationship, and the Right to a Human Mother." (2011).

[16]- Usuda, Haruo, et al. "Successful maintenance of key physiological parameters in preterm lambs treated with ex vivo uterine environment therapy for a period of 1 week." *American journal of obstetrics and gynecology* 217.4 (2017): 457-e1.

[17]- Roberts, Michelle. "Premature lambs kept alive in 'plastic bag'womb." *BBC News* (2017).

[18]- Gray, Brian W., et al. "Development of an artificial placenta IV: 24-hour venovenous extracorporeal life support in premature lambs." *ASAIO journal* 58.2 (2012): 148-154.

[19]- McLeod, Jennifer S., et al. "Splenic development and injury in premature lambs supported by the artificial placenta." *Journal of pediatric surgery* 54.6 (2019): 1147-1152.

[20]- Church, Joseph T., et al. "The artificial placenta: Continued lung development during extracorporeal support in a preterm lamb model." *Journal of pediatric surgery* 53.10 (2018): 1896-1903.

[21]- Coughlin, Megan A., et al. "An artificial placenta protects against lung injury and promotes continued lung development in extremely premature lambs." *ASAIO Journal* 65.7 (2019): 690-697.

[22]- El-Sabbagh, Ahmed M., et al. "Cerebral oxygenation of premature lambs supported by an artificial placenta." *ASAIO Journal* 64.4 (2018): 552-556.

[23]- Church, Joseph T., et al. "Effects of an artificial placenta on brain development and injury in premature lambs." *Journal of pediatric surgery* 53.6 (2018): 1234-1239.

[24]- McLeod, Jennifer S., et al. "Gastrointestinal mucosal development and injury in premature lambs supported by the artificial placenta." *Journal of pediatric surgery* 53.6 (2018): 1240-1245.

[25]- Gray, Brian W., et al. "Development of an artificial placenta V: 70 h veno-venous extracorporeal life support after ventilatory failure in premature lambs." *Journal of pediatric surgery* 48.1 (2013): 145-153.

[26]- Bryner, Benjamin, et al. "An extracorporeal artificial placenta supports extremely premature lambs for 1 week." *Journal of pediatric surgery* 50.1 (2015): 44-49.

[27]- Church, Joseph T., et al. "The artificial placenta rescues premature lambs from Ventilatory failure." *Journal of the American College of Surgeons* 225.4 (2017): S157-S158.

[28]- Miura, Yuichiro, et al. "Ex-vivo uterine environment (EVE) therapy induced limited fetal inflammation in a premature lamb model." *PloS one* 10.10 (2015): e0140701.

[29]- Miura, Yuichiro, et al. "Stable control of physiological parameters, but not infection, in preterm lambs maintained on ex vivo uterine environment therapy." *Artificial organs* 41.10 (2017): 959-968.

[30]- Usuda, Haruo, et al. "Successful maintenance of key physiological parameters in preterm lambs treated with ex vivo uterine environment therapy for a period of 1 week." *American journal of obstetrics and gynecology* 217.4 (2017): 457-e1.

[31]- Usuda, Haruo, et al. "Successful maintenance of key physiological parameters in preterm lambs treated with ex vivo uterine environment therapy for a period of 1 week." *American journal of obstetrics and gynecology* 217.4 (2017): 457-e1.

[32]- Miura, Yuichiro, et al. "A parallelized pumpless artificial placenta system significantly prolonged survival time in a preterm lamb model." *Artificial organs* 40.5 (2016): E61-E68.

[33]- Miura, Yuichiro, et al. "Novel modification of an artificial placenta: pumpless arteriovenous extracorporeal life support in a premature lamb model." *Pediatric research* 72.5 (2012): 490-494.

[34]- Usuda, Haruo, et al. "Successful use of an artificial placenta–based life support system to treat extremely preterm ovine fetuses compromised by intrauterine inflammation." *American journal of obstetrics and gynecology* 223.5 (2020): 755-e1.

[35]- Partridge, Emily A., et al. "An extra-uterine system to physiologically support the extreme premature lamb." *Nature communications* 8.1 (2017): 15112.

[36]- Ozawa, K., et al. "Fetal echocardiographic assessment of cardiovascular impact of prolonged support on EXTrauterine Environment for Neonatal Development (EXTEND) system." *Ultrasound in Obstetrics & Gynecology* 55.4 (2020): 516-522.

[37]- Rossidis, Avery C., et al. "Premature lambs exhibit normal mitochondrial respiration after long-term extrauterine support." *Fetal diagnosis and therapy* 46.5 (2019): 306-312.

[38]- Hornick, Matthew A., et al. "Technical feasibility of umbilical cannulation in midgestation lambs supported by the EXTra-uterine Environment for Neonatal Development (EXTEND)." *Artificial organs* 43.12 (2019): 1154-1161.

[39]- Hornick, Matthew A., et al. "Umbilical cannulation optimizes circuit flows in premature lambs supported by the EXTra-uterine Environment for Neonatal Development (EXTEND)." *The Journal of physiology* 596.9 (2018): 1575-1585.

[40]- Rossidis, Avery C., et al. "Chronically hypoxic fetal lambs supported by an extra-uterine device exhibit mitochondrial dysfunction and elevations of hypoxia inducible factor 1-alpha." *Fetal diagnosis and therapy* 45.3 (2019): 176-183.

[41]- Lawrence, Kendall M., et al. "Fetal hypoxemia causes abnormal myocardial development in a preterm ex utero fetal ovine model." *JCI insight* 3.24 (2018): e124338.

[42]- Lawrence, Kendall M., et al. "Chronic intrauterine hypoxia alters neurodevelopment in fetal sheep." *The Journal of thoracic and cardiovascular surgery* 157.5 (2019): 1982-1991.

[43]- McGovern, Patrick E., et al. "Ex utero extracorporeal support as a model for fetal hypoxia and brain dysmaturity." *The Annals of Thoracic Surgery* 109.3 (2020): 810-819.

[44]- Mejaddam, Ali Y., et al. "Erythropoietin prevents anemia and transfusions in extremely premature lambs supported by an extrauterine environment for neonatal development (extend)." *Fetal diagnosis and therapy* 46.4 (2019): 231-237.

[45]- McGovern, Patrick E., et al. "Neurologic outcomes of the premature lamb in an extrauterine environment for neonatal development." *Journal of Pediatric Surgery* 55.10 (2020): 2115-2123.

[46]- De Bie, Felix R., et al. "Pharmacokinetics and pharmacodynamics of sildenafil in fetal lambs on extracorporeal support." *Biomedicine & Pharmacotherapy* 143 (2021): 112161.

[47]- Eixarch, Elisenda, et al. "An artificial placenta experimental system in sheep: critical issues for successful transition and survival up to one week." *Biomedicines* 11.3 (2023): 702.

[48]- Charest-Pekeski, Alex J., et al. "Achieving sustained extrauterine life: challenges of an artificial placenta in fetal pigs as a model of the preterm human fetus." *Physiological Reports* 9.5 (2021): e14742.

[49]- McLeod, Jennifer S., et al. "Splenic development and injury in premature lambs supported by the artificial placenta." *Journal of pediatric surgery* 54.6 (2019): 1147-1152.

[50]- Charest-Pekeski, Alex J., et al. "Impact of the addition of a centrifugal pump in a preterm miniature pig model of the artificial placenta." *Frontiers in physiology* 13 (2022): 925772.

[51]- Usuda, Haruo, et al. "Artificial placenta support of extremely preterm ovine fetuses at the border of viability for up to 336 hours with maintenance of systemic circulation but reduced somatic and organ growth." *Frontiers in physiology* 14 (2023): 1219185.

[52]- Bridgeman, Jo. "Gard and Yates v GOSH, the Guardian and the UK: reflections on the legal process and the legal principles."

[53]- Martin, Elizabeth A. *Oxford concise medical dictionary*. New York: Oxford University Press, 2010.

[54]-Hendricks, Jennifer S. "Not of woman born: a scientific fantasy." *CasE W. rEs. l. rEv.* 62 (2011): 399.

[55]- Rieder, Travis N. "Saving or creating: which are we doing when we resuscitate extremely preterm infants?." *The American Journal of Bioethics* 17.8 (2017): 4-12.

[56]- Hayden, Dean, and Dominic Wilkinson. "Asymmetrical reasons, newborn infants, and resource allocation." *The American Journal of Bioethics* 17.8 (2017): 13-15.

[57]- Walker, Annika L., et al. "The long-term impact of maternal anxiety and depression postpartum and in early childhood on child and paternal mental health at 11–12 years follow-up." *Frontiers in psychiatry* 11 (2020): 562237.

[58]- Romanis, Elizabeth Chloe. "Artificial womb technology and the frontiers of human reproduction: conceptual differences and potential implications." *Journal of Medical Ethics* 44.11 (2018): 751-755.

[59]- Schultz, Jessica H. "Development of ectogenesis: how will artificial wombs affect the legal status of a fetus or embryo." *Chi.-Kent L. Rev.* 84 (2009): 877.

[60]- Bartlett, Robert H., et al. "Extracorporeal membrane oxygenation (ECMO) cardiopulmonary support in infancy." *The Journal of ExtraCorporeal Technology* 11.1 (1979): 26-41.

[61]- BARTLETT, ROBERT H., et al. "Extracorporeal Membrane Oxygenation for Newborn Respiratory Failure: Forty-five Cases." *Obstetrical & Gynecological Survey* 38.4 (1983): 211-213.

[62]- Gray, Brian W., Andrew W. Shaffer, and George B. Mychaliska. "Advances in neonatal extracorporeal support: the role of extracorporeal membrane oxygenation and the artificial placenta." *Clinics in perinatology* 39.2 (2012): 311-329.

[63]- Lawrence, Kendall M., et al. "Fetal hypoxemia causes abnormal myocardial development in a preterm ex utero fetal ovine model." *JCI insight* 3.24 (2018): e124338.

[64]- Rossidis, Avery C., et al. "Chronically hypoxic fetal lambs supported by an extra-uterine device exhibit mitochondrial dysfunction and elevations of hypoxia inducible factor 1-alpha." *Fetal diagnosis and therapy* 45.3 (2019): 176-183.

[65]- Lawrence, Kendall M., et al. "Chronic intrauterine hypoxia alters neurodevelopment in fetal sheep." *The Journal of thoracic and cardiovascular surgery* 157.5 (2019): 1982-1991.

[66]- McGovern, Patrick E., et al. "Ex utero extracorporeal support as a model for fetal hypoxia and brain dysmaturity." *The Annals of Thoracic Surgery* 109.3 (2020): 810-819.

[67]- De Bie, Felix R., et al. "Artificial placenta and womb technology: past, current, and future challenges towards clinical translation." *Prenatal diagnosis* 41.1 (2021): 145-158.

[68]- Bird, Stephen D. "Artificial placenta: Analysis of recent progress." *European Journal of Obstetrics & Gynecology and Reproductive Biology* 208 (2017): 61-70.

[69]- Usuda, Haruo, et al. "Successful use of an artificial placenta to support extremely preterm ovine fetuses at the border of viability." *American Journal of Obstetrics and Gynecology* 221.1 (2019): 69-e1.

[70]- Bulletti, Carlo, and Carlos Simon. "Bioengineered uterus: a path toward ectogenesis." *Fertility and Sterility* 112.3 (2019): 446-447.

[71]- Ghidini, Alessandro, et al. "In case you missed it: the prenatal diagnosis editors bring you the most significant advances of 2018." *Prenatal Diagnosis* 39.2 (2019): 61-69.

[72]- Miura, Yuichiro, et al. "Ex-vivo uterine environment (EVE) therapy induced limited fetal inflammation in a premature lamb model." *PloS one* 10.10 (2015): e0140701.

[73]- Smajdor, Anna. "The moral imperative for ectogenesis." *Cambridge Quarterly of Healthcare Ethics* 16.3 (2007): 336-345.

[74]- Smajdor, Anna. "The moral imperative for ectogenesis." *Cambridge Quarterly of Healthcare Ethics* 16.3 (2007): 336-345.

[75]- Chavatte-Palmer, Pascale, Rachel Levy, and P. Boileau. "Une reproduction sans utérus? État des lieux de l'ectogenèse." *Gynécologie obstétrique & fertilité* 40.11 (2012): 695-697.

[76]- Sandall, Jane, et al. "Short-term and long-term effects of caesarean section on the health of women and children." *The Lancet* 392.10155 (2018): 1349-1357.

[77]- Assad, Renato S., and Frank L. Hanley. "Artificial placenta—a need for fetal surgery?." *The Journal of Thoracic and Cardiovascular Surgery* 115.5 (1998): 1021-1022.

[78]- Kendal, Evie. "The perfect womb: Promoting equality of (fetal) opportunity." *Journal of bioethical inquiry* 14.2 (2017): 185-194.

[79]- Rowland, Robyn. "Technology and motherhood: reproductive choice reconsidered." *Signs: Journal of Women in Culture and Society* 12.3 (1987): 512-528.

[80]- Adkins, Victoria. "Impact of ectogenesis on the medicalisation of pregnancy and childbirth." *Journal of medical ethics* 47.4 (2021): 239-243.

[81]- Ovaere, Céline, et al. "Prenatal diagnosis and patient preferences in patients with neural tube defects around the advent of fetal surgery in Belgium and Holland." *Fetal diagnosis and therapy* 37.3 (2015): 226-234.

[82]- Smajdor, Anna. "Ethical challenges in fetal surgery." *Journal of Medical Ethics* 37.2 (2011): 88-91.

[83]- Romanis, Elizabeth Chloe. "Partial ectogenesis: freedom, equality and political perspective." *Journal of medical ethics* 46.2 (2020): 89-90.

[84]- Campo, Hannes, Irene Cervelló, and Carlos Simón. "Bioengineering the uterus: an overview of recent advances and future perspectives in reproductive medicine." *Annals of biomedical engineering* 45 (2017): 1710-1717.

[85]- Kennedy, Susan. "Willing mothers: ectogenesis and the role of gestational motherhood." *Journal of medical ethics* 46.5 (2020): 320-327.

[86]- Romanis, Elizabeth Chloe. "Artificial womb technology and the choice to Gestate ex utero: is partial Ectogenesis the business of the criminal law?." *Medical Law Review* 28.2 (2020): 342-374.

[87]- Kendal, Evie. "Unique benefits of ectogenesis outweigh potential harms." *Emerging Topics in Life Sciences* 3.6 (2019): 719-722.

[88]- Simonstein, Frida. "Artificial reproduction technologies (RTs)–all the way to the artificial womb?." *Medicine, Health Care and Philosophy* 9 (2006): 359-365.

[89]- Hooton, Victoria, and Elizabeth Chloe Romanis. "Artificial womb technology, pregnancy, and EU employment rights." *Journal of Law and the Biosciences* 9.1 (2022): lsac009.

[90]- Adamson, S. Lee, K. J. Whiteley, and B. Lowell Langille. "Pulsatile pressure-flow relations and pulse-wave propagation in the umbilical circulation of fetal sheep." *Circulation research* 70.4 (1992): 761-772.

[91]- Khulbe, Yashita, et al. "Artificial womb: opportunities and challenges for public health." *International Journal of Surgery* 109.3 (2023): 618-619.

[92]- Segers, Seppe. "The path toward ectogenesis: looking beyond the technical challenges." *BMC medical ethics* 22.1 (2021): 59.

[93]- Galbally, Megan, et al. "The role of oxytocin in mother-infant relations: a systematic review of human studies." *Harvard review of psychiatry* 19.1 (2011): 1-14.

[94]- Abecassis, Marion. "Artificial Wombs: the third era of human reproduction and the likely impact on French and US law." *Hastings Women's LJ* 27 (2016): 3.

[95]- Cavaliere, Giulia. "Gestation, equality and freedom: ectogenesis as a political perspective." *Journal of medical ethics* 46.2 (2020): 76-82.